PMID- 31809611
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 49
IP  - 7
DP  - 2020 Oct
TI  - Design and Optimization of PLGA Particles to Deliver Immunomodulatory Drugs for 
      the Prevention of Skin Allograft Rejection.
PG  - 840-857
LID - 10.1080/08820139.2019.1695134 [doi]
AB  - Background: Recent advancements in therapeutic strategies have attracted 
      considerable attention to control the acute organs and tissues rejection, which 
      is the main cause of mortality in transplant recipients. The long-term usage of 
      immunosuppressive drugs compromises the body immunity against simple infections 
      and decrease the patients' quality of life. Tolerance of allograft in recipients 
      without harming the rest of host immune system is the basic idea to develop the 
      therapeutic approaches after induction of donor-specific transplant. Methods: 
      Controlled and targeted delivery system by using biomimetic micro and 
      nanoparticles as carriers is an effective strategy to deplete the immune cells in 
      response to allograft in an antigen-specific manner. Polylactic-co-glycolic acid 
      (PLGA) is a biocompatible and biodegradable polymer, which has frequently being 
      used as drug delivery vehicle. Results: This review focuses on the biomedical 
      applications of PLGA based biomimetic micro and nano-sized particles in drug 
      delivery systems to prolong the survival of alloskin graft. Conclusion: We will 
      discuss the mediating factors for rejection of alloskin graft, selective 
      depletion of immune cells, controlled release mechanism, physiochemical 
      properties, size-based body distribution of PLGA particles and their effect on 
      overall host immune system.
FAU - Shahzad, Khawar Ali
AU  - Shahzad KA
AD  - Department of Microbiology and Immunology, Medical School, Southeast University , 
      Nanjing, Jiangsu, China.
AD  - School of Pharmacy, Taizhou Polytechnic College , Taizhou, Jiangsu, China.
FAU - Naeem, Muhammad
AU  - Naeem M
AUID- ORCID: 0000-0002-5311-3557
AD  - Institute of Pure and Applied Biology, Zoology Division, Bahauddin Zakariya 
      University , Multan, Pakistan.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Microbiology and Immunology, Medical School, Southeast University , 
      Nanjing, Jiangsu, China.
AD  - Department of Clinical Laboratory, Lishui District People's Hospital of Nanjing , 
      Nanjing, Jiangsu, China.
FAU - Wan, Xin
AU  - Wan X
AD  - Department of Microbiology and Immunology, Medical School, Southeast University , 
      Nanjing, Jiangsu, China.
FAU - Song, Shilong
AU  - Song S
AD  - Department of Microbiology and Immunology, Medical School, Southeast University , 
      Nanjing, Jiangsu, China.
FAU - Pei, Weiya
AU  - Pei W
AD  - Department of Microbiology and Immunology, Medical School, Southeast University , 
      Nanjing, Jiangsu, China.
FAU - Zhao, Chen
AU  - Zhao C
AD  - Department of Microbiology and Immunology, Medical School, Southeast University , 
      Nanjing, Jiangsu, China.
FAU - Jin, Xiaoxiao
AU  - Jin X
AD  - Department of Microbiology and Immunology, Medical School, Southeast University , 
      Nanjing, Jiangsu, China.
FAU - Shen, Chuanlai
AU  - Shen C
AUID- ORCID: 0000-0002-3748-3742
AD  - Department of Microbiology and Immunology, Medical School, Southeast University , 
      Nanjing, Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20191206
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (Antigens)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (Immunologic Factors)
RN  - 0 (Immunosuppressive Agents)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
SB  - IM
MH  - Allografts
MH  - Animals
MH  - Antigens/administration & dosage/immunology
MH  - Biomimetics/methods
MH  - Chemical Phenomena
MH  - Delayed-Action Preparations
MH  - *Drug Carriers/chemistry
MH  - Drug Delivery Systems
MH  - *Drug Design
MH  - Drug Development
MH  - Drug Liberation
MH  - Graft Rejection/drug therapy/immunology/*prevention & control
MH  - Graft Survival/drug effects/immunology
MH  - Humans
MH  - Immunologic Factors/*administration & dosage
MH  - Immunomodulation/drug effects
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Nanoparticles/chemistry
MH  - *Polylactic Acid-Polyglycolic Acid Copolymer/chemistry
MH  - Skin Transplantation/*adverse effects/methods
MH  - Transplantation, Homologous
OTO - NOTNLM
OT  - Acute rejection
OT  - PLGA
OT  - allograft
OT  - biomimetic
OT  - targeted delivery
EDAT- 2019/12/07 06:00
MHDA- 2021/07/15 06:00
CRDT- 2019/12/07 06:00
PHST- 2019/12/07 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2019/12/07 06:00 [entrez]
AID - 10.1080/08820139.2019.1695134 [doi]
PST - ppublish
SO  - Immunol Invest. 2020 Oct;49(7):840-857. doi: 10.1080/08820139.2019.1695134. Epub 
      2019 Dec 6.